Obinutuzumab Cuts Chronic GVHD After Transplant Edited by Katie Lennon May 07, 2026

https://www.medscape.com/viewarticle/obinutuzumab-cuts-chronic-gvhd-after-transplant-2026a1000eqr Prophylactic administration of obinutuzumab, a B-cell-depleting antibody, reduces the incidence of corticosteroid-requiring chronic graft-vs-host disease (cGVHD) at 1 year from 35.2% to 13.3% in allogeneic transplant recipients. The greatest benefit occurs in patients without preformed antibodies against Y chromosome-encoded minor histocompatibility antigens (H-Y), where the incidence drops to 8.6%.